Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Mutational status of VHL gene and its clinical importance in renal clear cell carcinoma.

Alves MR, Carneiro FC, Lavorato-Rocha AM, da Costa WH, da Cunha IW, de Cássio Zequi S, Guimaraes GC, Soares FA, Carraro DM, Rocha RM.

Virchows Arch. 2014 Sep;465(3):321-30. doi: 10.1007/s00428-014-1629-z. Epub 2014 Jul 16.

PMID:
25027579
2.

Genetic and epigenetic alterations in the von hippel-lindau gene: the influence on renal cancer prognosis.

Smits KM, Schouten LJ, van Dijk BA, Hulsbergen-van de Kaa CA, Wouters KA, Oosterwijk E, van Engeland M, van den Brandt PA.

Clin Cancer Res. 2008 Feb 1;14(3):782-7. doi: 10.1158/1078-0432.CCR-07-1753.

3.

[The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].

Gong K, Zhang N, Na X, Wu G, Yang XY, Xin DQ, Na YQ.

Zhonghua Wai Ke Za Zhi. 2005 Mar 15;43(6):390-3. Chinese.

PMID:
15854350
4.

Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma.

Patard JJ, Rioux-Leclercq N, Masson D, Zerrouki S, Jouan F, Collet N, Dubourg C, Lobel B, Denis M, Fergelot P.

Br J Cancer. 2009 Oct 20;101(8):1417-24. doi: 10.1038/sj.bjc.6605298. Epub 2009 Sep 15.

5.

Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors.

Moore LE, Nickerson ML, Brennan P, Toro JR, Jaeger E, Rinsky J, Han SS, Zaridze D, Matveev V, Janout V, Kollarova H, Bencko V, Navratilova M, Szeszenia-Dabrowska N, Mates D, Schmidt LS, Lenz P, Karami S, Linehan WM, Merino M, Chanock S, Boffetta P, Chow WH, Waldman FM, Rothman N.

PLoS Genet. 2011 Oct;7(10):e1002312. doi: 10.1371/journal.pgen.1002312. Epub 2011 Oct 13.

6.

Determination of the consequences of VHL mutations on VHL transcripts in renal cell carcinoma.

Taylor C, Craven RA, Harnden P, Selby PJ, Banks RE.

Int J Oncol. 2012 Oct;41(4):1229-40. doi: 10.3892/ijo.2012.1561. Epub 2012 Jul 20.

7.

Clear-cell papillary renal cell carcinoma: molecular and immunohistochemical analysis with emphasis on the von Hippel-Lindau gene and hypoxia-inducible factor pathway-related proteins.

Rohan SM, Xiao Y, Liang Y, Dudas ME, Al-Ahmadie HA, Fine SW, Gopalan A, Reuter VE, Rosenblum MK, Russo P, Tickoo SK.

Mod Pathol. 2011 Sep;24(9):1207-20. doi: 10.1038/modpathol.2011.80. Epub 2011 May 20.

8.

Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance.

Razafinjatovo C, Bihr S, Mischo A, Vogl U, Schmidinger M, Moch H, Schraml P.

BMC Cancer. 2016 Aug 17;16:638. doi: 10.1186/s12885-016-2688-0.

9.

Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma.

Patard JJ, Fergelot P, Karakiewicz PI, Klatte T, Trinh QD, Rioux-Leclercq N, Said JW, Belldegrun AS, Pantuck AJ.

Int J Cancer. 2008 Jul 15;123(2):395-400. doi: 10.1002/ijc.23496.

10.

PBRM1 and BAP1 as novel targets for renal cell carcinoma.

Brugarolas J.

Cancer J. 2013 Jul-Aug;19(4):324-32. doi: 10.1097/PPO.0b013e3182a102d1.

11.

The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.

Niu X, Zhang T, Liao L, Zhou L, Lindner DJ, Zhou M, Rini B, Yan Q, Yang H.

Oncogene. 2012 Feb 9;31(6):776-86. doi: 10.1038/onc.2011.266. Epub 2011 Jul 4.

12.

Combined deletion of Vhl, Trp53 and Kif3a causes cystic and neoplastic renal lesions.

Guinot A, Lehmann H, Wild PJ, Frew IJ.

J Pathol. 2016 Jul;239(3):365-73. doi: 10.1002/path.4736. Epub 2016 May 30.

13.

Analyses of Potential Predictive Markers and Response to Targeted Therapy in Patients with Advanced Clear-cell Renal Cell Carcinoma.

Song Y, Huang J, Shan L, Zhang HT.

Chin Med J (Engl). 2015 Aug 5;128(15):2026-33. doi: 10.4103/0366-6999.161353.

14.

Paraffin-embedded tissue is less accurate than frozen section analysis for determining VHL mutational status in sporadic renal cell carcinoma.

Verhoest G, Patard JJ, Fergelot P, Jouan F, Zerrouki S, Dreano S, Mottier S, Rioux-Leclercq N, Denis MG.

Urol Oncol. 2012 Jul-Aug;30(4):469-75. doi: 10.1016/j.urolonc.2010.07.005. Epub 2010 Sep 21.

15.

Dicer suppresses the malignant phenotype in VHL-deficient clear cell renal cell carcinoma by inhibiting HIF-2α.

Fan Y, Li H, Ma X, Gao Y, Bao X, Du Q, Ma M, Liu K, Yao Y, Huang Q, Zhang Y, Zhang X.

Oncotarget. 2016 Apr 5;7(14):18280-94. doi: 10.18632/oncotarget.7807.

16.

Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors.

Nickerson ML, Jaeger E, Shi Y, Durocher JA, Mahurkar S, Zaridze D, Matveev V, Janout V, Kollarova H, Bencko V, Navratilova M, Szeszenia-Dabrowska N, Mates D, Mukeria A, Holcatova I, Schmidt LS, Toro JR, Karami S, Hung R, Gerard GF, Linehan WM, Merino M, Zbar B, Boffetta P, Brennan P, Rothman N, Chow WH, Waldman FM, Moore LE.

Clin Cancer Res. 2008 Aug 1;14(15):4726-34. doi: 10.1158/1078-0432.CCR-07-4921.

17.

von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.

Choueiri TK, Vaziri SA, Jaeger E, Elson P, Wood L, Bhalla IP, Small EJ, Weinberg V, Sein N, Simko J, Golshayan AR, Sercia L, Zhou M, Waldman FM, Rini BI, Bukowski RM, Ganapathi R.

J Urol. 2008 Sep;180(3):860-5; discussion 865-6. doi: 10.1016/j.juro.2008.05.015. Epub 2008 Jul 17.

PMID:
18635227
18.

Tuberous sclerosis complex protein 1 expression is affected by VHL Gene alterations and HIF-1α production in sporadic clear-cell renal cell carcinoma.

Damjanovic SS, Ilic BB, Beleslin Cokic BB, Antic JA, Bankovic JZ, Milicevic IT, Rodic GS, Ilic DS, Todorovic VN, Puskas N, Tulic CD.

Exp Mol Pathol. 2016 Dec;101(3):323-331. doi: 10.1016/j.yexmp.2016.11.003. Epub 2016 Nov 12.

PMID:
27845047
19.

Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma.

Kim JH, Jung CW, Cho YH, Lee J, Lee SH, Kim HY, Park J, Park JO, Kim K, Kim WS, Park YS, Im YH, Kang WK, Park K.

Oncol Rep. 2005 May;13(5):859-64.

PMID:
15809750
20.

Biallelic inactivation of the von Hippel-Lindau tumor suppressor gene in sporadic renal cell carcinoma.

Hamano K, Esumi M, Igarashi H, Chino K, Mochida J, ISHIDA And H, Okada K.

J Urol. 2002 Feb;167(2 Pt 1):713-7.

PMID:
11792959

Supplemental Content

Support Center